HomeCompareBFRA vs BTI

BFRA vs BTI: Dividend Comparison 2026

BFRA yields 4.72% · BTI yields 5.38%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BTI wins by $10.5K in total portfolio value
10 years
BFRA
BFRA
● Live price
4.72%
Share price
$2.67
Annual div
$0.13
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$27.3K
Annual income
$638.40
Full BFRA calculator →
BTI
BTI
● Live price
5.38%
Share price
$58.47
Annual div
$3.15
5Y div CAGR
11.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$37.7K
Annual income
$2,786.64
Full BTI calculator →

Portfolio growth — BFRA vs BTI

📍 BTI pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBFRABTI
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BFRA + BTI cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BFRA pays
BTI pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BFRA
Annual income on $10K today (after 15% tax)
$401.12/yr
After 10yr DRIP, annual income (after tax)
$542.64/yr
BTI
Annual income on $10K today (after 15% tax)
$457.40/yr
After 10yr DRIP, annual income (after tax)
$2,368.64/yr
At 15% tax rate, BTI beats the other by $1,826.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BFRA + BTI for your $10,000?

BFRA: 50%BTI: 50%
100% BTI50/50100% BFRA
Portfolio after 10yr
$32.5K
Annual income
$1,712.52/yr
Blended yield
5.27%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on BTI right now

BFRA
Analyst Ratings
1
Buy
Consensus: Buy
BTI
Analyst Ratings
12
Buy
4
Hold
2
Sell
Consensus: Buy
Price Target
$40.00
-31.6% upside vs current
Range: $40.00 — $40.00
Altman Z
2.1
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BFRA buys
0
BTI buys
0
No recent congressional trades found for BFRA or BTI in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBFRABTI
Forward yield4.72%5.38%
Annual dividend / share$0.13$3.15
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%11.3%
Portfolio after 10y$27.3K$37.7K
Annual income after 10y$638.40$2,786.64
Total dividends collected$5.6K$14.3K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusBuyBuy

Year-by-year: BFRA vs BTI ($10,000, DRIP)

YearBFRA PortfolioBFRA Income/yrBTI PortfolioBTI Income/yrGap
1← crossover$11,172$471.91$11,299$598.92$127.00BTI
2$12,447$492.72$12,794$703.91$347.00BTI
3$13,831$513.03$14,518$829.07$687.00BTI
4$15,332$532.80$16,513$978.64$1.2KBTI
5$16,957$551.98$18,827$1,157.84$1.9KBTI
6$18,715$570.55$21,518$1,373.12$2.8KBTI
7$20,613$588.49$24,657$1,632.46$4.0KBTI
8$22,662$605.78$28,329$1,945.74$5.7KBTI
9$24,871$622.42$32,637$2,325.33$7.8KBTI
10$27,250$638.40$37,708$2,786.64$10.5KBTI

BFRA vs BTI: Complete Analysis 2026

BFRAStock

Biofrontera AG, a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products for the treatment of dermatological conditions and diseases caused primarily by exposure to sunlight that results in sun damage to the skin. Its principal product is Ameluz, a prescription drug for the treatment of lesion-directed and field-directed actinic keratosis. The company also offers BF-RhodoLED lamp, a photodynamic therapy for lesion-directed and field-directed treatment of actinic keratosis; and Belixos, an over-the-counter line of skin care cosmetic products. In addition, it is developing Ameluz for the treatment of field cancerization and nodular basal cell carcinoma. Further, the company's product portfolio includes Xepi, a prescription antibiotic cream for the treatment of impetigo; and Aktipak, a generic drug for the treatment of acne. It offers its products primarily in the United States, Europe, and Israel. The company has a collaboration and partnership agreement with Maruho Co., Ltd. Biofrontera AG was founded in 1997 and is headquartered in Leverkusen, Germany.

Full BFRA Calculator →

BTIConsumer Staples

British American Tobacco p.l.c. provides tobacco and nicotine products to consumers in the Americas, Europe, the Asia-Pacific, the Middle East, Africa, and the United States. It offers vapour, heated, and modern oral nicotine products; combustible cigarettes; and traditional oral products, such as snus and moist snuff. The company provides its products under the Vuse, glo, Velo, Grizzly, Kodiak, Dunhill, Kent, Lucky Strike, Pall Mall, Rothmans, Newport, Natural American Spirit, and Camel brands. The company distributes its products to retail outlets. British American Tobacco p.l.c. was founded in 1902 and is based in London, the United Kingdom.

Full BTI Calculator →
📬

Get this BFRA vs BTI comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BFRA vs SCHDBFRA vs JEPIBFRA vs OBFRA vs KOBFRA vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.